BMJ Group: GLP-1 Drug Linked to Heart Benefits for High-Risk Patients
August 06, 2026
August 06, 2026
LONDON, England, Aug. 6 (TNSjou) -- BMJ Group issued the following news release about The BMJ:
* * *
GLP-1 drug linked to heart benefits for high-risk patients
Findings from clinical practice will help inform shared decision making
-
Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular . . .
* * *
GLP-1 drug linked to heart benefits for high-risk patients
Findings from clinical practice will help inform shared decision making
-
Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular . . .